BridgeBio Pharma (BBIO) Other Non Operating Income (2018 - 2025)

BridgeBio Pharma has disclosed Other Non Operating Income across 8 years of filings, most recently posting $11.8 million for Q4 2025.

• Other Non Operating Income for Q4 2025 came in at $11.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $18.4 million (up 123.13% YoY), and the FY2025 annual result was $43.1 million, up 261.93% from the prior year.
• Other Non Operating Income came in at $11.8 million for Q4 2025 at BridgeBio Pharma, up from $6.5 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $28.3 million in Q4 2021 to a low of -$10.8 million in Q2 2022.
• The 5-year median for Other Non Operating Income is $5.8 million (2021), against an average of $5.4 million.
• Across the five-year window, Other Non Operating Income plunged 7700.0% in 2021 and jumped 1677.87% in 2024, its largest moves.
• BridgeBio Pharma's Other Non Operating Income stood at $28.3 million in 2021, then sank by 83.88% to $4.6 million in 2022, then surged by 377.59% to $21.8 million in 2023, then tumbled by 56.46% to $9.5 million in 2024, then rose by 24.62% to $11.8 million in 2025.
• The last three Other Non Operating Income figures came in at $11.8 million (Q4 2025), $6.5 million (Q2 2025), and $8.2 million (Q1 2025), per Business Quant data.